心房颤动、2型糖尿病与非维生素K拮抗剂口服抗凝药:综述
本综述分析心房颤动(AF)与2型糖尿病共病的流行病学与病理生理学,并基于非维生素K拮抗剂口服抗凝药(NOAC)3期临床试验中2型糖尿病亚组,指出NOAC在该人群绝对获益更大,建议进一步研究所有AF合并2型糖尿病患者的抗凝获益及NOAC相较维生素K拮抗剂的获益-风险。
要点
- AF患者卒中风险增加5倍,2型糖尿病为AF和卒中的独立危险因素。
- AF合并2型糖尿病时,绝对卒中发生率每年独立增加2%至3.5%。
- NOAC3期试验的2型糖尿病亚组显示NOAC绝对获益更大。
核心结论
- AF与2型糖尿病共存时血栓栓塞风险增加。
- 建议进一步研究所有AF合并2型糖尿病患者的抗凝潜在获益,以及NOAC相较维生素K拮抗剂潜在获益大于风险。
研究设计与样本
- 本文为综述,回顾AF与2型糖尿病共病的流行病学和病理生理学,并分析NOAC预防AF动脉血栓栓塞的3期临床试验中2型糖尿病亚组。
主要发现
- AF患者卒中风险增加5倍。
- AF合并2型糖尿病时,绝对卒中发生率每年独立增加2%至3.5%。
- NOAC3期临床试验的2型糖尿病亚组中,NOAC绝对获益更大。
关键数值与推荐
- AF患者卒中风险增加5倍。
- AF合并2型糖尿病时,绝对卒中发生率每年独立增加2%至3.5%。
临床怎么用
- 作者建议进一步研究所有AF合并2型糖尿病患者的抗凝潜在获益,以及NOAC相较维生素K拮抗剂潜在获益大于风险。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Atrial fibrillation (AF) is the most common cardiac arrhythmia and is associated with a 5-fold increase in the risk for stroke. Type 2 diabetes is an independent risk factor for both stroke and atrial fibrillation, and in the setting of AF, type 2 diabetes is independently associated with a 2% to 3.5% increase in absolute stroke rate per year. The overlap in the pathophysiologies of AF and type 2 diabetes are not well understood, and current practice guidelines provide few recommendations regarding patients with both conditions. OBSERVATIONS: In this article, we review the epidemiology and pathophysiology of the nexus of AF and type 2 diabetes. Furthermore, we analyze the subgroup of patients with type 2 diabetes enrolled in phase 3 clinical trials of non-vitamin K antagonist oral anticoagulants in prevention of arterial thromboembolism in AF, highlighting the greater absolute benefit of non-vitamin K oral anticoagulants in patients with type 2 diabetes. Finally, we offer recommendations on risk stratification and therapy for patients with concomitant AF and type 2 diabetes. CONCLUSIONS AND RELEVANCE: We highlight the increased thromboembolic risk with coexisting AF and type 2 diabetes. We recommend that further studies be done to evaluate the potential benefits of anticoagulation for all patients who have both and the potential for non-vitamin K oral anticoagulants to have greater benefits than risks over vitamin K antagonists.
引用
- Plitt A, McGuire DK, Giugliano RP, et al. Atrial Fibrillation, Type 2 Diabetes, and Non-Vitamin K Antagonist Oral Anticoagulants: A Review. JAMA Cardiol. 2017. PMID: 28122078. doi:10.1001/jamacardio.2016.5224
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。